The Short-term Efficacy Analysis Of Albumin-bound Paclitaxel In The Treatment Of Recurrent Ovarian Cancer

Objective:To observe the short-term clinical efficacy and safety of albumin-bound paclitaxel in the treatment of recurrent ovarian cancer.and explore the factors that may affect the clinical efficacy of albumin-bound paclitaxel in the treatment of recurrent ovarian cancer.Methods:Patients with recurrent ovarian cancer who were treated at the First Hospital of Jilin University from February 2010 to January 2020 were collected.Among them,52 patients were treated with albumin-bound paclitaxel.All patients were given albumin-bound paclitaxel 260 mg/m~2,d1,or albumin-bound paclitaxel 130 mg/m~2,d1 d8,combined with platinum(area under the carboplatin curve(AUC)=4-5,d2;loplatin 30mg/m~2 d1;Nidaplatin 75 mg/m~2,d1)or without intravenous infusion of platinum,3 to 4 weeks a course of treatment,until disease progression or intolerable adverse reactions occur.The efficacy was evaluated using the Response Evaluation Criteria In Solid Tumors(RECIST 1.1)or the CA125 Response Evaluation Standard of the gynecological cancer group(GCIG).The safety of patients was evaluated by the Common Terminology Criteria for Adverse Events(CTCAE)Version 5.0.Results:1.52 patients can evaluate the short-term efficacy,there were no CRs in 52 patients,18 patients had a PR(34.6%),24 patients had a SD(46.2%),10 patients had a PD(19.2%),and DCR was 80.8%,ORR was34.6%.2.Among the 52 patients,57.7%(30/52)had a platinum-free interval of less than 6 months(recurrence of platinum resistance),and42.3%(22/52)had a platinum-free interval of 6 months or more(platinum-sensitive relapse).The ORR of platinum-free interval<6months was 26.7%(8/30),and the ORR of platinum-free interval?6months was 45.5%(10/22),the difference between them was no statistical significance.3.The analysis of the correlation between different clinical data and efficacy showed that the patient's recent efficacy and age,ECOG score,tumor grade,FIGO stage at initial treatment,vascular cancer thrombus,previous chemotherapy regimen,recurrence site,treatment regimen,platinum-free interval,and so on,no significant statistical difference was found.4.whether there was lymph node metastasis at the time of initial diagnosis showed a statistical difference in ORR.5.Eighteen of the 52 patients had adverse reactions.The main adverse reactions were myelosuppression,peripheral neuropathy,fatigue,and liver function damage.Most of them were?to?degrees,which were all tolerable.Conclusions:1.The albumin-bound paclitaxel-based chemotherapy regimen shows a certain clinical effect in patients with recurrent ovarian cancer,and the incidence of adverse reactions is low and tolerable.It can be used as one of the treatment options for patients with recurrent ovarian cancer.2.Whether albumin-bound paclitaxel is used for relapse after first-line treatment/multi-line treatment,there is no statistical difference between the treatment effects,indicating that after multi-line relapse,a better effect can still be achieved.3.Regardless of platinum-resistant recurrence/platinum-sensitive recurrence,there is no statistical difference between their therapeutic effects,indicating that the efficacy of albumin-bound paclitaxel is not affected by platinum-resistance.4.Lymph node metastasis may be one of the factors affecting the short-term efficacy of albumin-bound paclitaxel in patients with recurrent ovarian cancer.